Brand dynamics

Group Real-Time Dynamics And Cutting-Edge Information In The Field Of One Health

R&D achievements realized! Jiankangyuan's benzoic acid argleatin tablets obtain drug registration certificate

Published Time:

2021-05-10

Recently, HealthGen (600380.SH) announced that its wholly-owned subsidiary, Shenzhen Haibin Pharmaceutical Co., Ltd., received the Drug Registration Certificate from the National Medical Products Administration for Alogliptin Benzoate Tablets (25mg).

 

According to the announcement, Alogliptin Benzoate Tablets (25mg specification) is an independently developed product of Shenzhen Haibin. This product is mainly used to treat type 2 diabetes. As monotherapy, it can be used as an adjunct to diet and exercise to improve glycemic control in patients with type 2 diabetes; it can also be used in combination with metformin hydrochloride to improve glycemic control in patients with type 2 diabetes in addition to diet and exercise. As the main chemical component of anti-diabetic drugs, alogliptin benzoate is the primary drug choice for weight management in overweight patients with type 2 diabetes.

 

Alogliptin benzoate tablets are one of the main drug varieties in the field of diabetes treatment. According to the website of the Center for Drug Evaluation of the National Medical Products Administration and the Salda database, as of now, there are a total of 9 domestic manufacturers (including HealthGen) of this approved drug. The approval of alogliptin benzoate tablets is a recognition by the state of HealthGen's listed drugs in terms of safety, efficacy, and quality control.

 

HealthGen adheres to technology-driven creation of healthy living, focusing on the real needs of patients, and has built four high-barrier complex preparation platforms. Among them, the respiratory preparation R&D platform has taken the lead in breaking through the international market monopoly and has become a leading domestic inhaler preparation, strongly supporting the advancement of the national health industry. At the starting point of the new decade of "Healthy China 2030," continuing the advantages of industrial foundation, we will increase the intensity of innovation and R&D in key areas such as chemical preparations, traditional Chinese medicine preparations, chemical raw materials and intermediates, and diagnostic reagents and equipment, continuously expanding the product lineup and categories, not only improving the efficiency of disease treatment, but also effectively providing more high-quality drug choices for chronic disease patients in China.

 

HealthGen has long focused on scientific research and innovation and continuously increased R&D investment. By the end of 2020, there were 137 products under research, with a very rich pipeline reserve. The successful approval of alogliptin benzoate tablets as a chemical preparation is a positive output of the group's acceleration of the realization of R&D results while consolidating its leading position in the field of scientific research. Innovation achieves results. Under the guidance of the national major strategy, it is believed that in the next ten years, the scale and value of China's major health industry will be unprecedentedly developed and amplified!